William J. Sandborn, MD, chief of gastroenterology at the University of California San Diego School of Medicine and study author, and colleagues conducted a double-blind, placebo-controlled phase 2 trial of ozanimod in 197 adults with moderate to severe ulcerative colitis. Patients were randomly assigned to receive ozanimod at a dose of 0.5 mg or 1 mg or placebo daily for up to 32 weeks. The primary outcome was clinical remission at eight weeks.
Here are six points:
1. The primary outcome occurred in 16 percent of the patients who received 1 mg of ozanimod.
2. The primary outcome occurred in 14 percent of the patients who received 0.5 mg of ozanimod.
3. Only 6 percent of the patients who received the placebo achieved the primary outcome.
4. At week 32, the rate of clinical remission was 21 percent in the group that received 1 mg of ozanimod.
5. The rate of clinical remission at week 32 was 26 percent in the group that received 0.5 mg of ozanimod.
6. The placebo group’s rate of clinical remission at week 32 was 6 percent.
More articles on GI & endoscopy:
Mederi Therapeutics launches 3rd generation of Stretta, Boston Scientific reports Q1 2016 financials & more — 5 GI company key notes
Gastroenterologist pay in the US, UK, Canada & Australia: 5 notes
Seres Therapeutics signs research agreements to support development of microbiome therapy for IBD: 3 points
